| Literature DB >> 1709154 |
E H Kraut1, T Fleming, M Segal, J A Neidhart, B C Behrens, J MacDonald.
Abstract
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.Entities:
Mesh:
Substances:
Year: 1991 PMID: 1709154 DOI: 10.1007/bf00194556
Source DB: PubMed Journal: Invest New Drugs ISSN: 0167-6997 Impact factor: 3.850